Small Molecules

19 Dec 2020 Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
18 Dec 2020 Metacrine Reports Positive Results from Phase 1 Trial of MET642
18 Dec 2020 Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
18 Dec 2020 Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease
18 Dec 2020 Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
18 Dec 2020 Cadent Therapeutics enters agreement to be acquired by Novartis
18 Dec 2020 Daiichi Sankyo Announces Phase 3 Study Results of mirogabalin of central neuropathic pain after spinal cord injury
17 Dec 2020 Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
16 Dec 2020 Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)
16 Dec 2020 Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain
16 Dec 2020 Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis
16 Dec 2020 U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
16 Dec 2020 Concentric Analgesics Announces Positive Topline Results from Phase 2 Clinical Trial of Vocacapsaicin (CA-008) in Total Knee Arthroplasty Surgery
14 Dec 2020 Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
14 Dec 2020 BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis
14 Dec 2020 Trixeo Aerosphere approved in the EU for maintenance treatment of COPD
14 Dec 2020 Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
11 Dec 2020 Doptelet® (avatrombopag) receives positive opinion from CHMP for treatment of ITP
11 Dec 2020 CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
11 Dec 2020 Janssen Receives Positive CHMP Opinion for SPRAVATO®▼ (Esketamine Nasal Spray) for the Rapid Reduction of Depressive Symptoms in a Psychiatric Emergency for Patients with Major Depressive Disorder
11 Dec 2020 QurAlis' Selective Kv7 Opener, a Drug Candidate for ALS, Demonstrates up to 20-Fold Increase in Potency and Dramatic Reduction in Side Effects Compared to Retigabine in Preclinical Models
11 Dec 2020 ViiV Healthcare Announces Positive CHMP Opinion for Rukobia (fostemsavir), a First-in-Class Attachment Inhibitor for the Treatment of Adults With Multidrug-Resistant HIV With Few Treatment Options Available
11 Dec 2020 Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
11 Dec 2020 Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
10 Dec 2020 Lilly Presents Positive Primary Outcome Data from monarchE that Builds on Previous Definitive Analysis for Verzenio®

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top